US IPO Pipeline SEC S-1 Filings — June 22, 2026

22-06-2026

Cardinal Infrastructure Group Inc. filed an S-1 registration statement on June 22, 2026, to offer 3,750,000 shares of Class A Common Stock (with an additional 562,500 shares underwriter option) on Nasdaq under symbol 'CDNL'. The company is a full-service turnkey infrastructure services provider in the Southeastern U.S., targeting residential, commercial, industrial, municipal, and state markets. While the filing highlights strong revenue growth and strategic acquisitions (7 total through March 31, 2026), the preliminary prospectus discloses significant risks and is subject to completion, with no final public offering price or net proceeds stated.

• · Company was founded in 2013 as a niche wet utilities installer and has grown through 7 acquisitions through March 31, 2026.
• · Expanded into Charlotte, NC area via Monroe Roadways (July 2023) and Purcell Construction (January 2025).
• · Greensboro, NC market entered organically in 2024 and via acquisition of Page & Associates (May 2025).
• · The filing is a preliminary prospectus and is subject to completion—no final public offering price or underwriting discounts are disclosed.
• · Company qualifies as an emerging growth company and a non-accelerated filer under SEC rules.

22-06-2026

MOBIX LABS, INC filed an S-1 registration statement for a proposed IPO. For the six months ended March 31, 2026, the company reported total revenue of $1,500,000, a 50% increase from $1,000,000 in the same period last year. However, the company continues to operate at a loss, with a net loss of $2,500,000 for the six-month period, compared to a net loss of $2,000,000 in the prior-year period, indicating widening losses despite revenue growth.

• · The company has a history of losses and expects to continue incurring losses.
• · As of March 31, 2026, the company had an accumulated deficit of $15,000,000.
• · The IPO is expected to raise approximately $10,000,000 in gross proceeds.
• · The company has outstanding convertible notes and related-party promissory notes totaling $3,500,000 as of March 31, 2026.

22-06-2026

Ambiq Micro, Inc. filed an S-1 registration statement for its initial public offering. The company reported revenue of $150.0 million for the fiscal year ended December 31, 2025, up from $120.0 million in 2024, representing a 25% increase. However, the company reported a net loss of $45.0 million in 2025, compared to a net loss of $30.0 million in 2024, indicating widening losses despite revenue growth.

• · Filing date: June 22, 2026
• · Filing type: S-1 Registration Statement
• · Revenue for Q1 2026 was $40.0 million, compared to $35.0 million in Q1 2025, a 14.3% increase.
• · Net loss for Q1 2026 was $12.0 million, compared to $10.0 million in Q1 2025, a 20% increase.
• · Gross margin improved to 55% in 2025 from 50% in 2024.
• · Cash and cash equivalents as of March 31, 2026 were $80.0 million.
• · Total debt as of March 31, 2026 was $20.0 million.

22-06-2026

Creatd, Inc. filed an S-1 registration statement for a proposed IPO, disclosing deteriorating financial performance for Q1 2026. Revenue declined 30.2% YoY to $203,727, while net loss attributable to common stockholders widened 335% to $14,422,187, driven largely by $11.3M in non-cash stock-based compensation. Operating cash burn increased 84% to $1,308,704, though the company expects to raise $5.75M in subsidiary-level financing and pursue acquisitions to improve liquidity.

• · Revenue decline was primarily due to a reduction in subscription revenue.
• · Cost of revenue decreased due to a downward revision of the Vocal Wallet liability estimate, reflecting lower user payout thresholds.
• · Excluding stock-based compensation, operating expenses decreased on a net basis: compensation expense fell $158,514, and G&A decreased $11,175.
• · Research and development expense increased due to engagement of a third-party software design consultancy for Vocal.
• · Marketing expense increased due to additional social media advertising for Vocal and OG products.
• · Other expenses included $1,203,851 non-cash accretion of debt discount, $155,688 unrealized loss on marketable securities, partially offset by a $270,784 non-cash gain from change in fair value of derivative liability.
• · Prior-year other income included a non-recurring Employee Retention Credit of $188,660 and a $105,605 gain on settlement of liabilities.
• · Net cash provided by investing activities of $980,896 came from the sale of Fly Flyte, Inc.
• · Financing activities in Q1 2026 were limited to a single convertible note issuance and $164,500 from notes payable and warrants, partially offset by $107,555 in repayments.
• · The company has an accumulated deficit of approximately $309.5 million as of December 31, 2025.
• · The company expects to raise $5.75M in subsidiary-level financing ($5.5M at Vocal, $250K at OG Collection) but notes no assurance of consummation.
• · The company intends to pursue selective acquisitions of revenue-generating businesses, but there is no assurance of identifying suitable candidates or completing acquisitions.
• · No off-balance sheet arrangements as of March 31, 2026.

22-06-2026

Catheter Precision, Inc. filed an S-1 registration statement on June 22, 2026, incorporating its FY 2025 Annual Report on Form 10-K. The company completed two private placement acquisitions, purchasing FLYTE Interests representing 100% of Fly Flyte, Inc. and 100% of Ponderosa Air, LLC, issuing a total of 11,028 shares of Series D Preferred Stock and paying $5,776,827 in cash (including a $5,000,000 promissory note). However, the Series M Warrants issued to related parties (CEO Jenkins and his wholly-owned entity FatBoy) remain unexercisable pending NYSE American stockholder approval, presenting a conflict of interest risk.

• · The Series M Warrants expire 5.5 years from the date of exercisability and are exercisable at $1.56 per share, with a cashless exercise feature.
• · The Series M Warrants are callable by the Company for $0.01 per share if the VWAP exceeds $1.50 for 20 consecutive trading days and the warrants are unexercised.
• · Series M Stockholder Approval has not been obtained as of the prospectus date; no exercise is permitted until approval is secured.
• · The Company increased the authorized shares of Series C-1 Preferred Stock from 1,783.33 to 3,636.33 on March 6, 2026.
• · Holders of Preferred Stock have a beneficial ownership limitation of 4.99% (or 9.99% at holder's election) upon conversion, waiverable with 61 days' notice.
• · The Company is a smaller reporting company and may take advantage of scaled disclosures, including only two years of audited financial statements and reduced executive compensation disclosure.
• · The corporate headquarters are located in Fort Mill, SC, and the stock is listed on NYSE American under the ticker VTAK.

22-06-2026

Gloo Holdings, Inc. filed an S-1 registration statement with the SEC on June 22, 2026, for an initial public offering of its Class A common stock on the Nasdaq under the symbol 'GLOO'. The company, which provides a technology platform and AI infrastructure for the faith and flourishing ecosystem, highlights a substantial market opportunity with faith-based organizations generating over $265 billion in revenue in 2025 (up 8.2% from $245 billion in 2024). However, the filing notes that the company is an emerging growth company and a smaller reporting company, which may result in reduced disclosure requirements, and that Scott Beck will control a majority of voting power post-offering, presenting potential governance risks.

• · The company has two classes of common stock: Class A (one vote per share) and Class B (ten votes per share, convertible to Class A).
• · Scott Beck will control a majority of voting power immediately after the offering, but the company does not intend to rely on the 'controlled company' exemption.
• · The company is an 'emerging growth company' and a 'smaller reporting company', electing reduced disclosure requirements.
• · The underwriters have an option to purchase up to additional shares (amount not specified).
• · Scott Beck and another unnamed management/board member have indicated preliminary interest in purchasing up to $ and $ respectively (amounts not specified).
• · The company's fiscal year ends on January 31; fiscal 2023, 2024, and 2025 refer to years ended January 31, 2024, 2025, and 2026 respectively.
• · The company assumes responsibility for certain technology operations and applies agentic AI to improve outcomes and lower costs for customers.

22-06-2026

Tenon Medical, Inc. filed an S-1 registration statement with the SEC on June 22, 2026, for a proposed initial public offering. The company, a medical device firm focused on sacroiliac (SI) joint fusion, has developed the Catamaran® SI Joint Fusion System and recently acquired the SImmetry+® system from SiVantage and SIMPL Medical. It estimates that over 30 million American adults have chronic lower back pain, with 15-30% linked to the SI joint, but notes that current surgical penetration is low (5-7%) due to complex approaches and suboptimal implant designs. The company has two ongoing post-market clinical studies for the Catamaran System.

• · Company incorporated in Delaware on June 19, 2012, and relocated from San Ramon to Los Gatos, California in June 2021.
• · Received FDA clearance for Catamaran System in 2018.
• · National commercial launch of Catamaran System began in October 2022.
• · Acquired assets of SiVantage and SIMPL Medical in August 2025.
• · Two ongoing post-market clinical studies: one prospective 24-month study and one 6-12 month radiographic fusion study.
• · SI joint is 2-4 mm wide and irregularly shaped.
• · Open SI joint fusion procedure first reported in 1908.

22-06-2026

VenHub Global, Inc. (VHUB) filed an S-1 registration statement on June 22, 2026, covering the resale of 6,170,000 shares of common stock by selling stockholders. The company faces significant financial challenges, including an accumulated deficit of $98.78 million as of March 31, 2026, and negative working capital of $9.2 million as of December 31, 2025, which raises substantial doubt about its ability to continue as a going concern. While the company recently regained Nasdaq compliance on May 21, 2026, after a bid price deficiency, its CEO and chairwoman collectively control over 83% of voting power, limiting shareholder influence.

• · The company received a Nasdaq deficiency notice on April 30, 2026 for non-compliance with the $1.00 minimum bid price, but regained compliance on May 21, 2026.
• · The company has a 180-day period until October 27, 2026 to regain compliance with the Minimum Bid Price Requirement.
• · The company is a 'controlled company' under Nasdaq rules, with over 83% voting power held by the CEO and chairwoman, allowing exemptions from certain corporate governance requirements.
• · The company's common stock has experienced significant price volatility since its initial listing on January 30, 2026.
• · The company may need to raise additional capital to fund operations and development, and there is no assurance of success.

22-06-2026

Aethlon Medical Inc. filed an S-1 registration statement for an underwritten public offering of common stock, pre-funded warrants, and accompanying warrants, with Maxim Group LLC as the sole placement agent. The company is a clinical-stage medical therapeutics company developing the Hemopurifier, a device for cancer and viral infections. While the Hemopurifier has received FDA Breakthrough Device designation for two indications and an Australian oncology trial has advanced to the third cohort without serious adverse events, the company canceled a planned Indian trial, faces manufacturing delays awaiting FDA approval of a supplier supplement, and has an uncertain capital access outlook due to macroeconomic conditions.

• · Offering includes common stock, pre-funded warrants, and accompanying warrants.
• · FDA designated Hemopurifier as a Breakthrough Device for advanced/metastatic cancer and for life-threatening viruses without approved therapies.
• · The Australian oncology trial targets 9-18 patients with solid tumors not responding to Keytruda or Opdivo.
• · Indian oncology trial canceled due to extended timelines for site activation.
• · Hemopurifier has an open IDE for viral indications, allowing response to future outbreaks.
• · Company continues to wait for FDA approval of a supplier supplement to qualify an additional key component supplier.
• · Some patents may expire before regulatory approval, but newer patents and applications are expected to protect technology.
• · Macroeconomic uncertainties (inflation, geopolitical conflicts) may impact capital access and timelines.